ClinicalTrials.gg
RecruitingNCT05470504Updated Aug 18, 2026

Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance

A Phase 2 interventional study of Pegvisomant in Insulin Receptor Mutation and Partial Lipodystrophy, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Insulin Resistance by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) — 3 open to participants now, 4 under way, none of them phase 3. Insulin Resistance · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Planned enrollment
15th of 23
25 · median 37
Started
2023
the only one that year
Phase 2
12 of 35
2 open now
Registered
34th of 35
by date

Among the 35 studies in Insulin Resistance by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), this one is the 15th largest by planned enrollment of the 23 interventional ones that give a count, is the only one that started in 2023, is one of 12 in phase 2, and was the 34th registered.

Insulin Resistance

2,974 studies on the registry are indexed under Insulin Resistance; 336 are open to participants now.

Browse Insulin Resistance studies →

Open to participants now

3 of the 35 studies in Insulin Resistance by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 241 Insulin Resistance studies recruiting now, 52 (22%) set no upper age limit and 157 (65%) stop at 75 or younger; 28 take children under 18; 112 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Insulin Resistance by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), or all of them as a file.
02

Study summary

Background:

Lipodystrophy (LD) syndromes are a group of rare disorders that affect how a person s body can store and use fat tissue. Many people with LDs become severely insulin resistant. Some people are insulin resistant because of a variant in the insulin receptor gene. Insulin resistance causes many health problems.

Objective:

To learn if blocking the effects of growth hormone in the body will help people with severe insulin resistance.

Eligibility:

Adults aged 18 to 65 years with either a known variant in the insulin receptor gene or with a diagnosis of partial LD.

Design:

Participants will have 2 hospital stays, about 1 month apart. Each stay will be 3 or 4 nights.

During each hospital stay, participants will have many tests. They will have a physical exam with blood tests. They will have all of their urine collected for a 24-hour period. They will have scans to measure their muscle, bone, and fat tissues. They will have tests to measure metabolism and insulin sensitivity. They may have an optional biopsy of fat tissue.

During the first hospital visit, participants will learn how to give themselves shots of a drug (pegvisomant) that blocks growth hormone. The drug is injected under the skin. Participants will continue to give themselves these shots once a day at home.

After the first hospital visit, participants will talk on the phone with members of the study team once each week. After 2 weeks they will have blood drawn for tests.

Participants will stop the shots after the second hospital visit.

Read the detailed description

STUDY DESCRIPTION

The role of growth hormone (GH) in mediating pathological consequences of inadequate lipid storage will be studied in rare patient populations with high lipolysis and severe metabolic syndrome. Specifically, patients with partial lipodystrophy and pathogenic variants in the insulin receptor gene (INSR) will be studied before and after 1 month of administration of pegvisomant (a GH receptor blocker).

OBJECTIVES

Primary Objective:

Establish proof of concept that GH blockade reduces adipose tissue lipolysis in humans with severe insulin resistance.

Secondary Objectives:

Determine the effects of pegvisomant on lipolytic products and IGF-1.

ENDPOINTS

Primary Endpoint:

Adipose tissue lipolysis measured by glycerol and palmitate rates of appearance using stable isotope tracers.

Secondary Endpoints:

Free fatty acids (FFA), glycerol, IGF-1.

03

Conditions studied

  • Insulin Receptor Mutation
  • Partial Lipodystrophy

Browse trials for

Keywords

  • Pegvisomant
  • Severe Insulin Resistance
  • Growth Hormone Inhibition
  • LIPOLYSIS
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible to participate in this study, an individual must meet all the following criteria:

  • Either

    • Known pathogenic variant in the insulin receptor gene, either dominant negative or recessive, OR
    • Clinical diagnosis of partial lipodystrophy based on reduction in adipose tissue outside the normal range in selected adipose depots (including, at a minimum, the gluteofemoral depot) with preservation of adipose tissue in other depots.
  • Male or female, aged 18-70 years.
  • Completed linear growth and puberty.

Exclusion criteria

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Use of niacin or other drugs that directly affect lipolysis within 8 weeks prior to enrollment.
  • Patients taking anticoagulants (blood thinning medications).
  • Use of non-steroidal anti-inflammatory medications (e.g., aspirin, ibuprofen) 2 weeks prior to the date (in patients who choose to undergo biopsy).
  • Changes in medications for diabetes or dyslipidemia within 2 weeks prior to enrollment.
  • Pregnancy or lactation.
  • For females of : inability or unwillingness to use during study participation and for an additional 1 month after the end of pegvisomant administration.
  • For males of reproductive potential: inability or unwillingness to use condoms or other methods to ensure effective contraception with partner during the study and for an additional 1 month after the end of pegvisomant administration.
  • Known allergic reactions pegvisomant or any of its components.
  • liver disease, evidenced by any of the following:

    • or AST >3 times the at screening.
    • Current known liver disease other than steatohepatitis (e.g., or viral hepatitis).
    • History of cirrhosis
  • Triglycerides >1500 mg/dL (non-fasting) or >1000 mg/dL (fasting) at screening.
  • In subjects with partial lipodystrophy only, >10% at screening.
  • Any other medical condition or medication that, in the judgement of the investigator, will increase risk to the subject or impede the measurement of study outcomes.
  • Inability of subject to understand or the unwillingness to sign a written document.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Other
    1

    open label pegvisomant

    Drug: Pegvisomant

Interventions

  • 30 mg subcutaneously every day for 4 weeks.

06

What researchers measure

Primary outcomes

  1. Glycerol rate of appearance (Ra) normalized to fat mass, Palmitate Ra normalized to fat mass

    Estimate the magnitude and variability of the effect of pegvisomant, 30 mg subcutaneously once daily for 1 month, on adipose tissue lipolysis rate in subjects with pathogenic variants in the insulin receptor and partial lipodystrophy.

    Time frame: 1 month

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) · Contactccopr@nih.gov · 800-411-1222
08

References and documents

Individual participant data

Plan to share: No — Result of the study will be disseminated to participants upon publication.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jan 2028, 60 months after the start.

Of 49 non-industry phase 2 interventional studies under Insulin Resistance, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 65. This study's planned 60 months is above that.

Counting every sponsor, half of 59 studies reached it within 45 months; a quarter within 25 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2022
First posted
Jul 22, 2022
StartActual
Jan 23, 2023
Primary completionEst.
Jan 30, 2028
CompletionEst.
Jan 30, 2028
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05470504
Responsible party
Sponsor
First posted
Jul 22, 2022
Start date
Jan 23, 2023
Primary completion
Jan 30, 2028 (estimated)
Completion
Jan 30, 2028 (estimated)
Last update
Aug 18, 2026

Study contacts

Megan S Startzell, R.N.
Contact
megan.startzell@nih.gov
(301) 402-6371
Rebecca J Brown, M.D.
Contact
brownrebecca@mail.nih.gov
(301) 594-0609
Rebecca J Brown, M.D.
principal investigator · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegvisomant

Start the discussion